Most Read Articles
Fiel Soliven, 01 Apr 2015
The effects canagliflozin on serum acid levels of type 2 diabetes mellitus patients and a subset who have hyperuricaemia were assessed in this review article.
16 Jun 2016
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, 30 Oct 2015
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
15 Jun 2016
Bicalutamide plus everolimus is a promising treatment for patients with castration-resistant prostate cancer (CRPC), based on a phase II clinical trial.

Statins exert no effect on systemic lupus risk

02 Aug 2017

Current statin use does not contribute to an increased risk of developing systemic lupus erythematosus (SLE) in individuals aged 40 years or above, according to a population-based cohort study. There is rather a signal of protection against the risk among long-term statin users.

Using data from the UK Clinical Practice Research Datalink, researchers identified 519,847 statin users and similar number of nonusers aged ≥40 years. The mean age was 63.1 years among users and 62.9 among nonusers. Follow-up in the group of statin users was divided into periods of current, recent and past exposure, with patients moving among these three exposure categories over time. Current statin users were also stratified according to duration of exposure: ≤1 year or >1 year. Analysis was performed using time-dependent Cox models.

Compared with nonusers, current statin users were not at high risk of developing SLE (adjusted hazard ratio [aHR], 0.75; 95 percent CI, 0.53 to 1.07). Furthermore, current statin use of >1 year was associated with a 38-percent lower risk of developing SLE (aHR, 0.62; 0.42 to 0.93), although this particular association was not observed when more specific definitions for SLE were used.

Statins are used to reduce the risk of cardiovascular morbidity and mortality in patients with hyperlipidaemia, hypertension or diabetes. The drugs demonstrate cholesterol-lowering activity, have anti-inflammatory and immunomodulatory properties, and possibly suppress the expression of ongoing autoimmune responses. A number of previous studies have shown that statins reduce the proinflammatory biomarkers and/or disease activity scores in patients with SLE. [J Rheumatol 2006;33:2361–3; Rheumatology 2007;46:1560–5; Clin Exp Rheumatol 2014;32:162–7]

The mechanisms by which statins may influence the risk of developing rheumatic autoimmune diseases are unknown, but the drugs have been shown to potentially promote regulatory T cell (Treg) differentiation in the periphery while blocking T helper (Th) 17 cell differentiation, which may be protective against SLE. Conversely, statins may also promote a shift in Th1/Th2 balance or lead to unstable peripheral Tregs, thus inducing autoimmunity. [Arthritis Res Ther 2010;12:R53; J Eur Acad Dermatol Venereol 2007;21:17–24; Nat Immunol 2009;10:1000–7]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 01 Apr 2015
The effects canagliflozin on serum acid levels of type 2 diabetes mellitus patients and a subset who have hyperuricaemia were assessed in this review article.
16 Jun 2016
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, 30 Oct 2015
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
15 Jun 2016
Bicalutamide plus everolimus is a promising treatment for patients with castration-resistant prostate cancer (CRPC), based on a phase II clinical trial.